DC
ZNTL icon

Decheng Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Decheng Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Hold
1,323,327
– – 0.47% 12
2025
Q4 		$1.79M Hold
1,323,327
– – 0.24% 15
2025
Q3 		$2M Hold
1,323,327
– – 0.35% 16
2025
Q2 		$1.54M Sell
1,323,327
-696,435
-34% -$919K 0.39% 16
2025
Q1 		$3.21M Sell
2,019,762
-318,333
-14% -$686K 0.9% 18
2024
Q4 		$7.08M Sell
2,338,095
-770,000
-25% -$2.52M 1.52% 14
2024
Q3 		$11.4M Buy
3,108,095
+37,653
+1% +$137K 2.71% 7
2024
Q2 		$12.6M Buy
3,070,442
+970,859
+46% +$10.8M 3.85% 4
2024
Q1 		$33.1M Hold
2,099,583
– – 4.44% 3
2023
Q4 		$31.8M Buy
+2,099,583
New +$30.6M 8.89% 2

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $250M AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $758M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return